Skip to main content

Table 3 Adverse events

From: Treatment of mucocutaneous manifestations in Behçet’s disease with anakinra: a pilot open-label study

 

Events

Incidence rate (per 100 days)

Anakinra 100 mg/day (194 total days)

Serious events

  Hospitalized to rule out thrombus

1

0.5

Non-serious events

  Injection site reaction

3

1.5

  Oral thrush

1

0.5

  Other

2

1.0

Anakinra 200 mg/day (1371 total days)

Serious events

  Pulmonary artery hypertension

1

0.1

  Pre-syncope

1

0.1

  Non-cardiac chest pain

1

0.1

Non-serious events

  Upper respiratory infection

5

0.4

  Alopecia

2

0.2

  Edema

2

0.2

  Vaginal yeast infection

1

0.1

  Other

9

0.7

Anakinra 300 mg/day (322 total days)

Serious events

  • None

0

0

Non-serious events

  • Upper respiratory infection

2

0.6

  • Vaginal yeast infection

1

0.3

  • Other

2

0.6